Our Journey

Led by Science
Driven by Dedication

Novlead Biotech was established in Nanjing, China in April 2018. Based on the self-developed Nitric Oxide Instant Generation Molecular Technology (NOGMT) platform, the company focuses on the R&D and production of innovative medical device products, and is committed to solving major clinical problems in the cardiopulmonary, respiratory and anti-infection fields, providing breakthrough clinical solutions in terms of gas detection and treatment.

The founding members of Novlead all have had many years of overseas study, scientific research and work experience, specializing in the R&D and commercialization of technologies related to medical gas detection and treatment. The core management team members all have executive experience in Fortune 500 companies. The company's R&D personnel account for 56.45%, of which masters and doctors account for 34.29%, and the team embraces many multi-disciplinary talents. The company has set up its R&D and production headquarter in the Jiangbei New District of Nanjing, a medical marketing center in Beijing, a consumer healthcare products operation base in Changsha, an overseas business platform in Haikou, and an overseas operation office in California, USA.

The company currently has five product pipelines, involving various fields related to gas detection and treatment. In China, it has obtained one Class II medical device registration certificate in January 2022, and one Class III medical device registration certificate in April 2022. At least three more Class III medical device registration certificates shall be obtained within five years. At the same time, the company is actively planning the overseas market layout, and the first EU CE registration certificate is expected to be obtained in the second half of 2022.

Novlead has now completed the B round of financing, and has received more than 100 million yuan in investment from well-known institutions such as Eli Lilly Asia Fund, Northern Lights Ventures, Materia Medica, and Eagle Alliance Capital. The company actively responds to the national development orientation of the 14th Five-Year Plan for the medical equipment industry, focusing on improving the intelligence and precision of monitoring equipment, critically neonatal treatment, and life support equipment. The company has been awarded a series of innovative enterprise honors, including the "Top Ten Entrepreneurship Star" presented by Nanjing in 2021.

Our vision

As an innovative technology-based medical company focusing on nitric oxide gas detection and treatment, our vision is to shape the high-end gas detection and treatment ecosystem, and to promote global progress of nitric oxide treatment for pulmonary hypertension and infectious diseases.

Our mission

Committed to the development of innovative nitric oxide gas generation and delivery systems to address unmet clinical needs

Dedicated to life science and medical business innovation, providing safe, effective and economical medical solutions

Rooted in material research, transforming high-quality products to improve the quality of human life

Novlead Values: No Evils, No Ceiling, No Excuse, No Hiding